Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

We recommend the following alternatives

  IP         H M R Hm Mk Mi Dm Z B Dg Pg Sc XP
REACTIVITY SENSITIVITY MW (kDa) Isotype
H M R Hm Mk Mi Dm Z B Pg Endogenous 42, 44 Mouse IgG2a

Product Usage Information

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol. Store at –20°C. Do not aliquot the antibodies.

Specificity / Sensitivity

Immobilized Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Mouse mAb binds only p44/42 MAP kinase activated by phosphorylation at Thr202/Tyr204. It is useful for immunoprecipitation kinase assays. The antibody does not significantly cross-react with SAPK/JNK or p38 MAP kinase phosphorylated at the corresponding residue or with nonphosphorylated MAPK.


Species Reactivity: Human, Mouse, Rat, Hamster, Monkey, Mink, D. melanogaster, Zebrafish, Bovine, Pig

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues around Thr202/Tyr204 of human p44 MAPK. Antibodies are immobilized by conjugation of carbohydrates to cross-linked agarose hydrazide beads.

Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059.


1.  Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.

2.  Baccarini, M. (2005) FEBS Lett 579, 3271-7.

3.  Meloche, S. and Pouysségur, J. (2007) Oncogene 26, 3227-39.

4.  Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310.

5.  Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74.

6.  Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75.

7.  Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505.

8.  Marais, R. et al. (1993) Cell 73, 381-93.

9.  Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24.

10.  Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13.


Entrez-Gene Id 5595 , 5594
Swiss-Prot Acc. P27361 , P28482


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
Sepharose® is a registered trademark of GE Healthcare.